J&J Monistat 1 joins Vagistat-1 in one-day yeast infection treatment market.
This article was originally published in The Tan Sheet
Executive Summary
MONISTAT 1 ENTERING ONE-DAY YEAST INFECTION TREATMENT MARKET under a licensing agreement between Johnson & Johnson and Bristol-Myers Squibb, the patent holder of the 6.5% tioconazole formulation. Bristol-Myers' Vagistat-1, which also contains 6.5% tioconazole, has been the sole entrant in the one-day vaginal yeast infection market until now. In stores nationwide starting June 15, Monistat 1 is being distributed by J&J's Personal Products Company.